Congenital malformations
Conditions
Interventions
Congenital malformation group, :None
Healthy control group:None
Sponsors
Dalian Women and Children's Medical Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Select children with congenital malformations who were diagnosed and admitted to our hospital from June 1, 2025, to June 1, 2026, along with healthy children matched as control subjects. 2. Children whose congenital malformations have been clearly diagnosed by our hospital's clinical team; the guardians of the children voluntarily participate in this study and have signed the informed consent form approved by our hospital's ethics committee.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| iPSC Line Establishment Success Rate;Differentiation Efficiency into Target Cell Type(s); | — |
Secondary
| Measure | Time frame |
|---|---|
| Validation of iPSC Pluripotency and Genomic Stability;Reproducibility of the Cellular Model;Validation of Disease-Relevant Phenotypes; | — |
Countries
China
Contacts
Public ContactZhang Qiaofeng
Dalian Women and Children's Medical Group
Outcome results
None listed